Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Five Under 5: Top Oncology Videos for the Week of 2/2

February 9th 2025

The top 5 videos of the week cover insights in lung cancer, multiple myeloma, breast cancer, and follicular lymphoma.

Pembrolizumab Provides Clinical Benefit in Previously Treated Advanced Clear Cell Gynecologic Cancer

February 9th 2025

Pembrolizumab warrants further evaluation in patients with previously treated advanced clear cell gynecologic cancer in a randomized clinical trial.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Dr Mekhail on a Case Study of Early-Stage, Nonmetastatic Lung Cancer

February 2nd 2025

Tarek Mekhail, MD, MSc, FRCSI, FRCSEd, discusses a case study of a patient with early-stage, nonmetastatic lung adenocarcinoma.

Dr Levy on the Development and Clinical Use of ADCs in NSCLC

February 2nd 2025

Benjamin P. Levy, MD, discusses the current clinical and developmental statuses of several ADCs for patients with non–small cell lung cancer.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research

February 2nd 2025

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Dr Hales on the Use of Post-Operative Radiotherapy in NSCLC

February 2nd 2025

Russell Hales, MD, discusses clinical data that challenge the use of post-operative radiotherapy in patients with non–small cell lung cancer.

Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC

February 2nd 2025

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer

February 1st 2025

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Dr Shields on Key ADRIATIC Trial Data With Adjuvant Durvalumab in LS-SCLC

February 1st 2025

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Dr Langer on the Evolution of Adjuvant Immunotherapy in NSCLC

February 1st 2025

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?

January 31st 2025

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

A Close Look at Clinical Trials in Oncology and Beyond: Looking Toward the Future

January 31st 2025

In this last episode, experts underscore the importance of incorporating the patient voice into clinical trial processes.

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer

January 31st 2025

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

A Close Look at Clinical Trials in Oncology and Beyond: Efforts at Northwell

January 31st 2025

In this episode, experts discuss the growth and strategic development of Northwell's cancer clinical trial programs.

A Close Look at Clinical Trials in Oncology and Beyond: Leveraging AI

January 31st 2025

In this episode, experts discuss how artificial intelligence tools can enhance clinical trial recruitment, improve workforce efficiency, and more.

Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC

January 31st 2025

The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.